Hydroa vacciniforme in three alternate siblings

1971 ◽  
Vol 103 (2) ◽  
pp. 224-225 ◽  
Author(s):  
R. Annamalai
Keyword(s):  
1978 ◽  
Vol 114 (8) ◽  
pp. 1193-1196 ◽  
Author(s):  
D. R. Bickers
Keyword(s):  

1979 ◽  
Vol 41 (5) ◽  
pp. 864-871
Author(s):  
Koji MATSUDA ◽  
Tomoyuki KAWATSU ◽  
Yoshiharu MIKI
Keyword(s):  

1990 ◽  
Vol 52 (5) ◽  
pp. 911-916 ◽  
Author(s):  
Hiroto TERASHI ◽  
Kazumoto KATAGIRI ◽  
Sakuhei FUJIWARA ◽  
Hiroshi SHINKAI ◽  
Hiroki ICHIKAWA ◽  
...  

2010 ◽  
Vol 22 (3) ◽  
pp. 312 ◽  
Author(s):  
Hae-Young Park ◽  
Ji-Hye Park ◽  
Kyung-Tae Lee ◽  
Dong-Youn Lee ◽  
Joo-Heung Lee ◽  
...  
Keyword(s):  

2020 ◽  
Vol 21 (23) ◽  
pp. 9314
Author(s):  
Chien-Chin Chen ◽  
Kung-Chao Chang ◽  
L Jeffrey Medeiros ◽  
Julia Yu-Yun Lee

Hydroa vacciniforme (HV) is a rare form of photosensitivity disorder in children and is frequently associated with Epstein–Barr virus (EBV) infection, whereas HV-like lymphoproliferative disorders (HVLPD) describe a spectrum of EBV-associated T-cell or natural killer (NK)-cell lymphoproliferations with HV-like cutaneous manifestations, including EBV-positive HV, atypical HV, and HV-like lymphoma. Classic HV occurs in childhood with papulovesicules on sun-exposed areas, which is usually induced by sunlight and ultraviolet irradiation, and mostly resolves by early adult life. Unlike classic HV, atypical or severe HV manifests itself as recurrent papulovesicular eruptions in sun-exposed and sun-protected areas associated occasionally with facial edema, fever, lymphadenopathy, oculomucosal lesions, gastrointestinal involvement, and hepatosplenomegaly. Notably, atypical or severe HV may progress to EBV-associated systemic T-cell or natural killer (NK)-cell lymphoma after a chronic course. Although rare in the United States and Europe, atypical or severe HV and HV-like lymphoma are predominantly reported in children from Asia and Latin America with high EBV DNA levels, low numbers of NK cells, and T cell clones in the blood. In comparison with the conservative treatment used for patients with classic HV, systemic therapy such as immunomodulatory agents is recommended as the first-line therapy for patients with atypical or severe HV. This review aims to provide an integrated overview of current evidence and knowledge of HV and HVLPD to elucidate the pathophysiology, practical issues, environmental factors, and the impact of EBV infection.


2016 ◽  
Vol 36 (3) ◽  
pp. 268-270
Author(s):  
Sang-Yong Shin ◽  
Chang-Hun Park ◽  
Duck Cho ◽  
Hee-Jin Kim ◽  
Sun-Hee Kim

2015 ◽  
Vol 173 (3) ◽  
pp. 801-805 ◽  
Author(s):  
H. Nomura ◽  
H. Suzuki ◽  
S. Egami ◽  
T. Yokoyama ◽  
M. Sugiura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document